Florida’s Medical Marijuana Law

Presented by:

Jason D. Winn, Esq.
General Counsel, FOMA

October 2017
The FOMA Governmental Affairs

- Jason D. Winn, Esquire

  Jason is a 1996 graduate of the University of Maryland and received his Juris Doctorate from Nova Southeastern University – Shepard Broad Law in Ft. Lauderdale, Florida. Mr. Winn was admitted to the Florida Bar in September 2001. From 2001 to 2004, Mr. Winn worked for the Assistant Public Defender in the Fifth Judicial Circuit where he conducted over 15 jury trials, numerous non-jury trials, and many hearings including, violations of probation, restitution, and early termination motions for defendants in Juvenile, Misdemeanor and Felony Court. Mr. Winn was also an adjunct professor at Lake Sumter Community College teaching Business Law during this time. In 2003, Mr. Winn was appointed by Governor Bush to serve a one year term on the Judicial Nominating Commission for Judicial Compensation Judges. From 2004-2006 Mr. Winn worked for the law office of Clyde M. Taylor, Jr. focusing on both state and federal criminal defense and parole violation hearings. In 2006, he opened his own practice, where he is the managing partner and continues to focus on criminal, administrative, governmental, civil, wills, and trusts. Mr. Winn currently serves as general counsel for the Florida Osteopathic Medical Association (FOMA), the Florida Podiatric Medical Association (FPMA), and the Florida Society of Hearing Healthcare Professionals (FSHHP). He is a member of the Florida Bar, Tallahassee Bar, Legal Services of Florida, a lifetime member of the state Florida Association of Criminal Defense Lawyers, and the local FACDL chapter. As a member of the Tallahassee Bar, Mr. Winn volunteers his legal services to the Wakulla County Senior Citizens Center through the Legal Services of North Florida.
Table of Contents

+ Passage of Amendment 2
+ 2017a Legislative Session Highlights
+ Medical Cannabis Administrative and Regulatory Timeline
+ Florida Medical Marijuana Evolving and Fluid Process
+ Florida Medical Marijuana Law for Dispensing Organizations
+ Florida Medical Marijuana Law for Physicians and Patients
+ Federal Guidelines and Medical Marijuana
Passage of Amendment 2
The Amendment 2 ballot initiative was amended to the Florida Constitution on November 8, 2016, with 71% of the vote – 11% higher than the required 60% supermajority threshold.

The amendment officially became effective on January 3, 2017.
### Expands Treatment

<table>
<thead>
<tr>
<th>Cancer</th>
<th>Epilepsy</th>
<th>Glaucoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human Immune Deficiency virus (HIV)</td>
<td>Acquired Immune Deficiency syndrome (AIDS)</td>
<td>Post-Traumatic Stress Disorder (PTSD)</td>
</tr>
<tr>
<td>Amyotrophic Lateral Sclerosis (ALS)</td>
<td>Crohn's Disease</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td>Multiple Sclerosis (MS)</td>
<td>Or other debilitating medical conditions of the same kind or class as or comparable to those enumerated, and for which a physician believes that the medical use of marijuana would likely outweigh the potential health risks for a patient.</td>
<td></td>
</tr>
</tbody>
</table>
2017a Legislative Session Highlights
Definitions

- “Marijuana” to mean all parts of any plant of the genus Cannabis, whether growing or not; the seeds thereof; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant or its seeds or resin, including low-THC cannabis, which are dispensed from a MMTC for medical use by a qualified patient.

- “Caregiver” to mean a resident of the state who has agreed to assist with a qualified patient’s medical use of marijuana, has a caregiver identification card, and meets the requirements for caregivers established in the section.

- “Chronic nonmalignant pain” to mean pain that is caused by a qualifying medical condition or that originates from a qualifying medical condition and persists beyond the usual course of that qualifying medical condition.

- “Close relative” to mean a spouse, parent, sibling, grandparent, child, or grandchild, whether related by whole or half blood, by marriage, or by adoption.

- “Edibles” to mean commercially produced food items made with marijuana oil, but no other form of marijuana, that are produced and dispensed by a MMTC.

- “Marijuana testing laboratory” to mean a facility that collects and analyzes marijuana samples from a MMTC and has been certified by the department pursuant to s. 381.988, F.S.
Definitions

- “Medical use” to mean the acquisition, possession, use, delivery, transfer, or administration of marijuana authorized by a physician certification. The term does not include:
  - Possession, use, or administration of marijuana that was not purchased or acquired from a MMTC.
  - Possession, use, or administration of marijuana in a form for smoking, in the form of commercially produced food items other than edibles, or of marijuana seeds or flower, except for flower in a sealed, tamper-proof receptacle for vaping.
  - Use or administration of any form or amount of marijuana in a manner that is inconsistent with the qualified physician’s directions or physician certification.
  - Transfer of marijuana to a person other than the qualified patient for whom it was authorized or the qualified patient’s caregiver on behalf of the qualified patient.
  - Use or administration of marijuana in the following locations:
    - On any form of public transportation, except for low-THC cannabis.
    - In any public place, except for low-THC cannabis.
    - In a qualified patient’s place of employment, except when permitted by his or her employer.
    - In a state correctional institution, as defined in s. 944.02, F.S., or a correctional institution, as defined in s. 944.241, F.S.
    - On the grounds of a preschool, primary school, or secondary school, except as provided in s. 1006.062, F.S.
    - In a school bus, a vehicle, an aircraft, or a motorboat, except for low-THC cannabis.
Definitions

- “Qualified physician” to mean a person who holds an active, unrestricted license as an allopathic physician under chapter 458 or as an osteopathic physician under chapter 459 and is in compliance with the physician education requirements.

- “Terminal condition” to mean a progressive disease or medical or surgical condition that causes significant functional impairment, is not considered by a treating physician to be reversible without the administration of life-sustaining procedures, and will result in death within 1 year after diagnosis if the condition runs its normal course.
Medical Marijuana Treatment Centers (MMTC)

- Grandfathers existing 7 dispensing organizations and re-classifies entities as licensed MMTCs.

- DOH is required to license 10 new MMTCs by October 3, 2017:
  - By August 1, 2017 – 5 who placed second during the first round of licensure;
  - By October 3, 2017 – 5 new MMTCs;
    - 1 must be a member of the *Pigford vs. Glickman* or *Black Farmer Litigation* and is a member of the Black Farmers and Agriculturalists Association-Florida Chapter
    - 4 open competitive, of which 2 citrus producers may be provided preferential scoring.

- Additionally, within 6 months of the registration of 100,000 qualified patients in the registry and at each additional 100,000 patients thereafter, the DOH must license 4 new MMTCs.
2017a Legislative Session Highlights

MMTCs

- **Dispensary Caps** - authorized to establish a maximum of 25 dispensaries statewide. The statewide maximum number of dispensaries is increased by 5 per MMTC each time the registry adds 100,000 additional qualified patients;

- Establishes new MMTC application process;

- Regulates MMTC changes of ownership;

- Establishes additional MMTC requirements;

- Establishes MMTC cultivation standards;

- Provides for MMTC processing and testing standards;

- Revises packaging and labeling requirements;

- Establishes dispensing requirements - MMTCs may not dispense more than a 70-day supply to a qualified patient and may not dispense directly to a minor patient;

- Limits MMTC Advertising;

- Provides for additional background screening requirements;

- Preempts the regulation of cultivation, processing, and delivery of marijuana is preempted to the State.
Other Regulations

- Revises policies for physicians certifying patient use of Medical Marijuana;
- Alters patient and caregiver requirements relating to Medical marijuana;
- Expands the qualifying medical conditions to include those enumerated within Amendment 2;
- Requires the electronic registry must be accessible on-line to law enforcement agencies, qualified physicians, and medical marijuana treatment centers (MMTC) to verify patient certifications;
- Requires the Department of Law Enforcement to develop training available to all law enforcement agencies that covers the legal parameters of marijuana-related activities by qualified patients, caregivers, MMTCs, and medical marijuana testing labs;
- Appropriates $100,000 in recurring funds from the Highway Safety Operating Trust Fund to the DHSMV for the purpose of training additional law enforcement officers as drug recognition experts;
- Appropriates $5,000,000 in nonrecurring funds from the Highway Safety Operating Trust Fund to the DHSMV to implement the impaired driving education campaign;
- Appropriates $500,000 in nonrecurring funds from the General Revenue Fund to the DOH to implement the statewide marijuana education and use prevention campaign;
- Appropriates $750,000 in nonrecurring General Revenue funds for the Coalition to conduct medical cannabis research.
Timeline of Medical Marijuana in Florida
Timeline of Medical Marijuana in Florida

- June 16, 2014
  Governor Scott signs the Compassionate Medical Cannabis Act of 2014

- June 18, 2014
  First Round – DOH begins the Rule Development Process

- Sept. 9, 2014
  Department published Final Rule

- Sept. 9-12, 2014
  Rule Challenges filed

- Nov. 14, 2014
  Final Order – Judge Watkins rules against DOH
Timeline of Medical Marijuana in Florida

Dec. 30, 2014
Second Round – Rule Development

Feb. 6, 2015
Department publishes new Rule

March 24, 2015
Rule challenged

May 27, 2015
DOH Rules upheld by Judge Watkins – Challenge dismissed

July 8, 2015
Accepted applications for Dispensing Organizations slots
Timeline of Medical Marijuana in Florida

- Nov. 23, 2015: Approved Dispensing Organizations announced
- Dec. 11-14, 2015: Petitioners (13 petitions filed) Challenge Nursery Selection Process
- March 25, 2016: Gov. Scott signs HB 307 – adopting major revisions to the Compassionate Medical Cannabis Act
- November 8, 2016: Amendment 2 Passes
- Disposition of petitions to be determined
- June 2017: Legislature Adopts and Governor signs Amendment 2 Implementing bill
Florida Medical Marijuana
an Evolving and Fluid Process
Florida Medical Marijuana
an Evolving and Fluid Process

To date:

- Over 1000 doctors have completed the course requirements to certify medical marijuana;

- Over 36,000 patients have been registered on the Medical Marijuana Use Registry.
A Change in Federal Policy Toward Medical Cannabis

- **S.683 - Compassionate Access, Research Expansion, and Respect States (CARERS) Act of 2015 (Introduced 03-10-2015)** – Sponsor Sen. Corey Booker (D- NJ) – 15 Senate Co-sponsors (Bipartisan Support); 3-10-2015: Referred to the Committee on Judiciary;


The aforementioned measures failed to garner Congressional approval. However, they do signal a potential policy shift at the federal level (bipartisan) in support of medical cannabis. The legislation would have remedied many state-federal conflicts over medical marijuana;

Congress has passed legislation to address physician, banking and medical cannabis industry concerns. December 2015 Congress passed the Omnibus spending bill which restricts federal law enforcement activities in states that have legalized medical cannabis (restrictions apply to funds provided in the omnibus package);

In August 2016 the DEA and FDA decided not to revise marijuana’s Schedule I status (no accepted medical use and high potential for abuse). "The DEA and the FDA continue to believe that scientifically valid and well-controlled clinical trials conducted under investigational new drug (IND) applications are the most appropriate way to conduct research on the medicinal uses of marijuana," said a statement from the DEA” (CNN August 12, 2016).

Florida Medical Marijuana Law – Identification Card

Front of Card

[Image of a Florida Medical Marijuana Id Card]
This Compassionate Use Registry identification card is issued by the Florida Department of Health under authority of Section 381.986, F.S. and Rule 64-4.011, F.A.C. This card indicates that the pictured patient or legal representative is registered in the Compassionate Use Registry. All patients and legal representatives must have a Compassionate Use Registry identification card to possess, purchase, or use medical cannabis. Marijuana remains illegal under federal law.

An application for a replacement card must be submitted to the Department within 10 days of a name, address, or assigned legal representative change. Renewal applications must be submitted 45 days prior to expiration.

The Compassionate Use Registry can be accessed at:
https://curegistry.flhealth.gov/

The Office of Compassionate Use can be reached by visiting:
http://www.floridahealth.gov/OCU
The DOH is required to begin issuing ID cards to qualified patients and caregivers by October 3, 2017. The ID cards must be resistant to tampering and counterfeiting and include, at a minimum:

- The name, address, and date of birth of the qualified patient or caregiver;
- A full-face, passport-type, color photograph of the qualified patient or caregiver taken within the 90 days immediately preceding registration or the Florida driver license or Florida identification card photograph of the qualified patient or caregiver obtained directly from the Department of Highway Safety and Motor Vehicles (DHSMV);
- Identification as a qualified patient or a caregiver;
- The unique numeric identifier used for the qualified patient in the medical marijuana use registry;
- For a caregiver, the name and unique numeric identifier of the caregiver and the qualified;
- patient or patients that the caregiver is assisting;
- The expiration date of the identification card.

Prior to issuing an ID card to a minor, the DOH must receive written consent from the minor’s parent or guardian. Patients and caregivers must return their ID cards within five business days after their registration is revoked.
A qualified patient or caregiver in possession of marijuana or a marijuana delivery device who fails or refuses to present his or her marijuana use registry identification card upon the request of a law enforcement officer commits a misdemeanor of the second degree, punishable as provided in s. 775.082 or s. 775.083, unless it can be determined through the medical marijuana use registry that the person is authorized to be in possession of that marijuana or marijuana delivery device;

A person charged with a violation of this paragraph may not be convicted if, before or at the time of his or her court or hearing appearance, the person produces in court or to the clerk of the court in which the charge is pending a medical marijuana use registry identification card issued to him or her which is valid at the time of his or her arrest. The clerk of the court is authorized to dismiss such case at any time before the defendant’s appearance in court. The clerk of the court may assess a fee of $5 for dismissing the case under this paragraph;

Any person who possesses or manufactures a blank, forged, stolen, fictitious, fraudulent, counterfeit, or otherwise unlawfully issued medical marijuana use registry identification card commits a felony of the third degree, punishable as provided in s. 775.082, s. 775.083, or s. 775.084.
Florida Medical Marijuana Law for Medical Marijuana Treatment Centers
Florida Medical Marijuana Law for MMTCs

- A person or entity that cultivates, processes, distributes, sells, or dispenses marijuana, as defined in s. 29(b)(4), Art. X of the State Constitution, and is not licensed as a medical marijuana treatment center violates s. 893.13 and is subject to the penalties provided therein.

- A person who manufactures, distributes, sells, gives, or possesses with the intent to manufacture, distribute, sell, or give marijuana or a marijuana delivery device that he or she holds out to have originated from a licensed medical marijuana treatment center but that is counterfeit commits a felony of the third degree:
  - punishable as provided in s. 775.082, s. 775.083, or s. 775.084.
  - “counterfeit” means marijuana; a marijuana delivery device; or a marijuana or marijuana delivery device container, seal, or label which, without authorization, bears the trademark, trade name, or other identifying mark, imprint, or device, or any likeness thereof, of a licensed medical marijuana treatment center and which thereby falsely purports or is represented to be the product of, or to have been distributed by, that licensed medical marijuana treatment facility.
# Florida Medical Marijuana Law for MMTCs

## Department of Health Approved Medical Marijuana Treatment Centers

<table>
<thead>
<tr>
<th>Name</th>
<th>Authorization Stage (1 = cultivation, 2 = processing, 3 = dispensing)</th>
<th>Locations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trulieve</td>
<td>(3) dispensing</td>
<td>Tallahassee, Tampa, Clearwater, Pensacola, Miami, Edgewater, Lady Lake, Jacksonville, St. Petersburg, Bradenton, delivery</td>
</tr>
<tr>
<td>Surterra Therapeutics</td>
<td>(3) dispensing</td>
<td>Tallahassee, Tampa, delivery</td>
</tr>
<tr>
<td>Modern Health Concepts</td>
<td>(3) dispensing</td>
<td>Miami, delivery</td>
</tr>
<tr>
<td>Knox Medical</td>
<td>(3) dispensing</td>
<td>Tallahassee, Gainesville, Orlando, Jacksonville, delivery</td>
</tr>
<tr>
<td>Aphria (CHT Medical)</td>
<td>(3) dispensing</td>
<td>Delivery</td>
</tr>
<tr>
<td>The Green Solution</td>
<td>(3) dispensing</td>
<td>Delivery</td>
</tr>
<tr>
<td>GrowHealthy</td>
<td>(1) cultivation</td>
<td>N/A</td>
</tr>
<tr>
<td>3 Boys Farm</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Loop’s Nursery &amp; Greenhouses, Inc.</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Plants of Ruskin, Inc.</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Sunbulb Company, Inc</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Treadwell Nursery</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
An MMTC is approved by the Department of Health to cultivate, process, transport, and dispense low-THC cannabis and medical marijuana.

Safety and Security Measures

- MMTCs must implement and maintain certain safety and security measures which include:
  - Maintain a fully operational surveillance and alarm system;
  - Store medical marijuana in secured, locked rooms or a vault;
  - Have at least 2 employees of the dispensing organization or of a contracted security agency be on the dispensing organization premises at all times;
Safety and Security Measures

- Safety and security measures continued...
  - All employees must wear a photo identification badge while on the premises;
  - All visitors must wear a visitor’s pass at all times while on the premises;
  - Must implement an alcohol and drug free workplace policy;
  - Report to local law enforcement within 24 hours - the theft, diversion, or loss of low-THC cannabis or medical cannabis;
Florida Medical Marijuana Law for MMTCs

Safety and Security Measures

- Safety and security measures continued...
  - Ensure the outdoor premises has sufficient lighting from dusk until dawn;
  - Dispensing is authorized between the hours of 7 a.m. and 9 p.m. However, the dispensing organizations are able to perform all other operations and deliveries of its product 24 hours a day.
Transportation

- Transportation requirements for MMTCs:
  - Maintain a marijuana transportation manifest in any vehicle transporting marijuana. The manifest must be generated from a MMTC’s seed-to-sale tracking system and include:
    - Date and approximate time of departure and arrival;
    - Name, location address, and license number of the originating MMTC;
    - Name and address of recipient of the delivery;
    - Quantity and form of any marijuana or delivery device being transported;
    - Delivery vehicle make and model and license plate number;
    - Name and signature of the MMTC employees delivering the product.
Transportation

- Transportation requirements for MMTCs:
  - A copy of the manifest must be provided to each individual, MMTC, or marijuana laboratory that receives a delivery;
  - The individual, or a representative of the center or laboratory, must sign a copy of the manifest acknowledging receipt;
  - An individual transporting marijuana or a marijuana delivery device must present a copy of the relevant manifest and his or her employee ID card to a law enforcement office upon request;
  - MMTCs and marijuana testing laboratories must retain copies of all marijuana transportation manifests for at least 3 years;
Transportation

- Transportation requirements for MMTCs:
  - Ensure only vehicles in good-working order are used to transport medical marijuana or medical marijuana delivery devices;
  - Requires medical marijuana and marijuana delivery devices to be locked in a separate compartment or container within the vehicle;
  - Employees must be in possession of their employee identification card at all times when transporting marijuana or marijuana delivery devices;
  - Have at least two persons in a vehicle transporting medical marijuana or medical marijuana delivery devices. At least one person must remain in the vehicle throughout the delivery process;
  - Provide specific safety and security training to those employees transporting medical marijuana or medical marijuana delivery devices.
Transportation

A person transporting marijuana or marijuana delivery devices on behalf of a medical marijuana treatment center or marijuana testing laboratory who fails or refuses to present a transportation manifest upon the request of a law enforcement officer commits a misdemeanor of the second degree, punishable as provided in s. 775.082 or s. 775.083.
Growing

- **When growing** medical marijuana, MMTCs:
  - May use pesticides determined by the DOH and Department of Agriculture and Consumer Services;
  - Must be in an enclosed structure and in a room separate from any other plant;
  - Must inspect seeds and growing plants for plant pests that endanger or threaten the state;
  - Must perform fumigation or treatment of plants, or remove and destroy infested or infected plants, in accordance with chapter 581 and any rules adopted thereunder.
Florida Medical Marijuana Law for MMTCs

Processing

- When processing medical marijuana, MMTCs must:
  - Process the medical marijuana in an enclosure separate from other plants or products;
  - Comply with department rules when processing marijuana with hydrocarbon solvents or other solvents or gases exhibiting potential toxicity to humans;
  - Package the low-THC cannabis or medical marijuana in compliance with the U.S. Poison Prevention Packaging Act (15 U.S.C. §§1471-1477);
  - Test the processed marijuana using a medical marijuana testing laboratory before it is dispensed.
Florida Medical Marijuana Law for MMTCs

Processing

- Package the medical marijuana in a receptacle that has a firmly affixed and legible label stating the following information:
  - The marijuana or low-THC cannabis meets the requirements;
  - The name of the medical marijuana treatment center from which the marijuana originates;
  - The batch number and harvest number from which the marijuana originates and the date dispensed;
  - The name of the physician who issued the physician certification;
  - The name of the patient;
  - The product name, if applicable, and dosage form, including concentration of tetrahydrocannabinol and cannabidiol. The product name may not contain wording commonly associated with products marketed by or to children;
  - The recommended dose;
  - A warning that it is illegal to transfer medical marijuana to another person;
  - A marijuana universal symbol developed by the department.
Florida Medical Marijuana Law for MMTCs

Processing

- The medical marijuana treatment center shall include in each package a patient package insert with information on the specific product;

- Each edible shall be individually sealed in plain, opaque wrapping marked only with the marijuana universal symbol. Where practical, each edible shall be marked with the marijuana universal symbol. In addition to the packaging and labeling requirements;

- Edible receptacles must be plain, opaque, and white without depictions of the product or images other than the medical marijuana treatment center's department-approved logo and the marijuana universal symbol. The receptacle must also include a list all of the edible's ingredients, storage instructions, an expiration date, a legible and prominent warning to keep away from children and pets, and a warning that the edible has not been produced or inspected pursuant to federal food safety laws.
Dispensing

- When dispensing low-THC cannabis or medical cannabis, dispensing organizations must:
  - Not dispense more than 70 day supply to a patient or the patient’s legal representative;
  - The employee dispensing the low-THC cannabis or medical cannabis must enter into the medical marijuana use registry his or her name or unique employee identifier;
  - Must verify that the qualified patient and the caregiver, if applicable, each have an active registration in the medical marijuana use registry and an active and valid medical marijuana use registry identification card, the amount and type of marijuana dispensed matches the physician certification in the medical marijuana use registry for that qualified patient, and the physician certification has not already been filled;
  - May not dispense marijuana to a qualified patient who is younger than 18 years of age. If the qualified patient is younger than 18 years of age, marijuana may only be dispensed to the qualified patient’s caregiver.
Dispensing

- May not dispense or sell any other type of cannabis, alcohol, or illicit drug-related product, including pipes, bongs, or wrapping papers, other than a marijuana delivery device required for the medical use of marijuana and which is specified in a physician certification.

- Must, upon dispensing the marijuana or marijuana delivery device, record in the registry the date, time, quantity, and form of marijuana dispensed; the type of marijuana delivery device dispensed; and the name and medical marijuana use registry identification number of the qualified patient or caregiver to whom the marijuana delivery device was dispensed.

- Must ensure that patient records are not visible to anyone other than the qualified patient, his or her caregiver, and authorized medical marijuana treatment center employees.
Florida Medical Marijuana Law for Physicians and Patients
Penalties

• A qualified physician commits a misdemeanor of the first degree, punishable as provided in s. 775.082 or s. 775.083, if the qualified physician issues a physician certification for the medical use of marijuana for a patient without a reasonable belief that the patient is suffering from a qualifying medical condition.

• A person who fraudulently represents that he or she has a qualifying medical condition to a qualified physician for the purpose of being issued a physician certification commits a misdemeanor of the first degree, punishable as provided in s. 775.082 or s. 775.083.

• A qualified physician who issues a physician certification for marijuana or a marijuana delivery device and receives compensation from a medical marijuana treatment center related to the issuance of a physician certification for marijuana or a marijuana delivery device is subject to disciplinary action under the applicable practice act and s. 456.072(1)(n).

• The Board of Osteopathic Medicine and Board of Medicine have grounds for disciplinary action if the issuing physician certification, as defined in s. 381.986, is performed in a manner not in compliance with the requirements set forth in statute and rule.
Other debilitating medical conditions of the same kind or class as or comparable to those enumerated, and for which a physician believes that the medical use of marijuana would likely outweigh the potential health risks for a patient.

<table>
<thead>
<tr>
<th>Cancer</th>
<th>Epilepsy</th>
<th>Glaucoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human Immune Deficiency virus (HIV)</td>
<td>Acquired Immune Deficiency syndrome (AIDS)</td>
<td>Post-Traumatic Stress Disorder (PTSD)</td>
</tr>
<tr>
<td>Amyotrophic Lateral Sclerosis (ALS)</td>
<td>Crohn's Disease</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td>Multiple Sclerosis (MS)</td>
<td>Terminal Condition</td>
<td>Chronic Nonmalignant Pain</td>
</tr>
</tbody>
</table>
Qualifying Physicians

- Hold an active, unrestricted license as a physician under chapter 458, F.S. or an osteopathic physician under chapter 459, F.S.;

- Not be a medical director employed by a Medical Marijuana Treatment Center;

- Successfully complete the 2-hour medical marijuana course;

- Register as a qualifying physician with the Department of Health.
Physician Course Requirements

- In order to issue physician certifications or to be a medical director of an MMTC, the statute requires that a physician complete a **2-hour training course prior to being approved to issue physician certifications** and at each licensure renewal.

- The course must encompass the requirements of the section and any rules adopted to implement the section.

- Further, it requires the Florida Medical Association (FMA) or the Florida Osteopathic Medical Association (FOMA) to develop and offer the course annually.

- The FMA or FOMA may not charge more than $500 to take the course and may offer the course in a distance learning format, including online.
Regulations for Certifying Physicians

Restrictions on Issuing Physician Certifications

A physician may not issue a physician certification:

- If he or she is employed by an MMTC or marijuana testing laboratory;
- If he or she has any direct or indirect economic interest in an MMTC or marijuana testing laboratory.
Regulations for Certifying Physicians

Procedures for Issuing a Physician Certification

A physician must:

- Conduct an in-person physical examination of the patient and a full assessment of the patient’s medical history;
- Diagnose the patient with at least one qualifying medical condition;
- Determine that the patient’s use of marijuana would outweigh the risks - if the patient is under the age of 18, two physicians must make this determination;
- Determine whether the patient is pregnant - physicians may only certify pregnant patients for low-THC cannabis;
- Review the patient’s controlled substance prescription history in the prescription drug monitoring program database;
A physician must:

- Review the medical marijuana use registry (registry) to determine that the patient does not have an active physician certification from another qualified physician;

- Register as the issuer of the physician certification on the registry. The physician must also:
  - Enter the contents of the physician certification into the registry including the patient’s qualifying condition, the dosage not to exceed the daily dose amount determined by the DOH, the amount and forms of marijuana authorized for the patient, and any types of marijuana delivery devices needed by the patient;
  - Update the registry if any change is made to the physician certification;
  - Deactivate the patient’s registration when the physician no longer recommends the patient medically use marijuana.
Procedures for Issuing a Physician Certification

Informed Consent

- A physician must also obtain the patient’s voluntary and written informed consent each time he or she issues the patient a physician certification.

- The physician must use a standardized form created by the Board of Medicine (BOM) or the Board of Osteopathic Medicine (BOOM) and, if the patient is a minor, the physician must also obtain the consent of the patient’s parent or legal guardian.
The standardized informed consent form must include:

- The Federal Government’s classification of marijuana as a Schedule I controlled substance;
- The approval and oversight status of marijuana by the Food and Drug Administration;
- The current state of research on the efficacy of marijuana to treat the qualifying conditions set forth in this section;
- The potential for addiction;
- The potential effect that marijuana may have on a patient’s coordination, motor skills, and cognition, including a warning against operating heavy machinery, operating a motor vehicle, or engaging in activities that require a person to be alert or respond quickly;
- The potential side effects of marijuana use;
- The risks, benefits, and drug interactions of marijuana;
- That the patient’s de-identified health information contained in the physician certification and registry may be used for research purposes.
Medical Marijuana Consent Form

A qualified physician may not delegate the responsibility of obtaining written informed consent to another person. The qualified patient or the patient’s parent or legal guardian if the patient is a minor must initial each section of this consent form to indicate that the physician explained the information and, along with the qualified physician, must sign and date the informed consent form.


   The federal government has classified marijuana as a Schedule I controlled substance. Schedule I substances are defined, in part, as having (1) a high potential for abuse; (2) no currently accepted medical use in treatment in the United States; and (3) a lack of accepted safety for use under medical supervision. Federal law prohibits the manufacture, distribution, and possession of marijuana even in states, such as Florida, which have modified their state laws to treat marijuana as a medicine.

b. The approval and oversight status of marijuana by the Food and Drug Administration.

   Marijuana has not been approved by the Food and Drug Administration for marketing as a drug. Therefore, the “manufacture” of marijuana for medical use is not subject to any federal standards, quality control, or other oversight. Marijuana may contain unknown quantities of active ingredients, which may vary in potency, impurities, contaminants, and substances in addition to THC, which is the primary psychoactive chemical component of marijuana.

c. The potential for addiction.

   Some studies suggest that the use of marijuana by individuals may lead to a tolerance to, dependence on, or addiction to marijuana. I understand that if I increase the use of marijuana, I should contact Dr. (name of qualified physician).

d. The potential effect that marijuana may have on a patient’s coordination, motor skills, and cognition, including a warning against operating heavy machinery, operating a motor vehicle, or engaging in activities that require a person to be alert or respond quickly.

   The use of marijuana can affect coordination, motor skills, and cognition, i.e., the ability to think, judge, and reason. Driving under the influence of cannabis can double the risk of crashing, which correlates if alcohol is also influencing the driver. While using medical marijuana, I should not drive, operate heavy machinery, or engage in any activities that require me to be alert and respond quickly, and I should not participate in activities that may be dangerous to myself or others. I understand that if I drive while under the influence of marijuana, I can be arrested for “driving under the influence.”

e. The potential side effects of medical marijuana use.

   Potential side effects from the use of marijuana include, but are not limited to, the following: dizziness, anxiety, confusion, sedation, low blood pressure, impairment of short-term memory, euphoria, difficulty in completing complex tasks, suppression of the body’s immune system, and the possibility of death. Marijuana may also affect the production of sex hormones that lead to adverse effects, inability to concentrate, impaired motor skills, paranoia, psychotic symptoms, general anxiety, depression, and/or restlessness. Marijuana may exacerbate schizophrenia in persons predisposed to that disorder. In addition, the use of medical marijuana may cause me to talk or eat in excess, alter my perception of time and space, and impair my judgment. Many medical authorities claim that use of medical marijuana, especially by persons younger than 25, can result in long-term problems with attention, memory, learning, drug abuse, and schizophrenia.

   I understand that using marijuana while consuming alcohol is not recommended. Additional side effects may become present when using both alcohol and marijuana.

   I agree to contact Dr. (name of qualified physician) if I experience any of the side effects listed above, or if I become depressed or psychotic, have suicidal thoughts, or experience crying spells. I will also contact Dr. (name of qualified physician) if I experience respiratory problems, changes in my normal sleeping patterns, extreme fatigue, increased irritability, or begin to withdraw from my family and/or friends.

f. The risks, benefits, and drug interactions of marijuana.

   Signs of withdrawal can include: feelings of depression, sadness, irritability, insomnia, restlessness, agitation, loss of appetite, trouble concentrating, sleep disturbances, and unusual tiredness.

   Symptoms of marijuana overdose include, but are not limited to, nausea, vomiting, hacking cough, disturbances in heart rhythms, numbness in the hands, feet, arms or legs, anxiety attacks and incapacitation. If I experience these symptoms, I agree to contact Dr. (name of qualified physician) immediately or go to the nearest emergency room.

   Numerous drugs are known to interact with marijuana and not all drug interactions are known. Some mixtures of medications can lead to serious and even fatal consequences. I agree to follow the directions of Dr. (name of qualified physician) regarding the use of prescription medication.
Medical Marijuana Consent Form

and nonprescription medication. I will advise any of my treating physician(s) of my use of medical marijuana.

Marijuana may increase the risk of bleeding, low blood pressure, elevated blood sugar, liver enzymes, and other bodily systems when taken with herbs and supplements. I agree to contact Dr. immediately or go to the nearest emergency room if these symptoms occur.

I understand that medical marijuana may have serious risks and may cause low birthweight or other abnormalities in babies. I will advise Dr. if I become pregnant, try to get pregnant, or will be breastfeeding.

h. The current state of research on the efficacy of marijuana to treat the qualifying conditions set forth in this section.

Cancer
- There is insufficient evidence to support or refute the conclusion that cannabinoids are an effective treatment for cancers, including glioma.
  
  There is evidence to suggest that cannabinoids (and the endocannabinoid system more generally) play a role in the cancer regulation processes. Due to a lack of recent, high quality reviews, a research gap exists concerning the effectiveness of cannabis or cannabinoids in treating cancer in general.

- There is conclusive evidence that oral cannabinoids are effective in treating cancer in the treatment of chemotherapy-induced nausea and vomiting.
  
  There is insufficient evidence to support or refute the conclusion that cannabinoids are an effective treatment for cancer-associated anorexia-cachexia syndrome and anorexia nervosa.

Epilepsy
- There is insufficient evidence to support or refute the conclusion that cannabinoids are an effective treatment for epilepsy.
  
  Recent systematic reviews were unable to identify any randomized controlled trials evaluating the efficacy of cannabinoids for the treatment of epilepsy. Currently available clinical data therefore consist solely of uncontrolled case series, which do not provide high-quality evidence of efficacy. Randomized trials of the efficacy of cannabinoids for different forms of epilepsy have been completed and await publication.

Glioma
- There is limited evidence that cannabinoids are an ineffective treatment for improving intracranial pressure associated with glioma.

Lower intracranial pressure is a key target for glioma treatments. Non-randomized studies in healthy volunteers and glioma patients have shown short-term reductions in intracranial pressure with oral, topical eye drops, and intravenous cannabinoids, suggesting the potential for therapeutic benefit. A good-quality systematic review identified a single small trial that found no effect of two cannabinoids, given as an ophthalmal spray, on intracranial pressure. The quality of evidence for the finding of no effect is limited. However, to be effective, treatments targeting lowering intracranial pressure must provide continual rather than transient reductions in intracranial pressure. To date, those studies showing positive effects have shown only short-term benefit on intracranial pressure (hours), suggesting a limited potential for cannabinoids in the treatment of glioma.

Positive status for human immunodeficiency virus
- There is limited evidence that cannabis and oral cannabinoids are effective in increasing appetite and decreasing weight loss associated with HIV/AIDS.
  
  There does not appear to be good-quality primary literature that reported on cannabinoids or cannabis as effective treatments for AIDS wasting syndrome.

Acquired immune deficiency syndrome
- There is limited evidence that cannabis and oral cannabinoids are effective in increasing appetite and decreasing weight loss associated with HIV/AIDS.
  
  There does not appear to be good-quality primary literature that reported on cannabis or cannabinoids as effective treatments for AIDS wasting syndrome.

Post-traumatic stress disorder
- There is limited evidence (a single, small fair-quality trial) that miloate is effective for improving symptoms of posttraumatic stress disorder.
  
  A single, small crossover trial suggests potential benefit from the pharmaceutical cannabinoid miloate. This limited evidence is most applicable to male veterans and contrasts with non-randomized studies showing limited evidence of a statistical association between cannabis use (plant derived forms) and increased severity of posttraumatic stress disorder symptoms among individuals with posttraumatic stress disorder. There is other trials that are in the process of being conducted and if successfully completed, they will add substantially to the knowledge base.

Amyotrophic lateral sclerosis
- There is insufficient evidence that cannabinoids are an effective treatment for symptoms associated with amyotrophic lateral sclerosis.
  
  Two small studies investigated the effect of cannabinoid on symptoms associated with ALS. Although there were no differences from placebo in either trial, the...
sample sizes were small, the duration of the studies was short, and the dose of

dronabinol may have been too small to ascertain any activity. The effect of
cannabis was not investigated.

___ Crohn’s disease
• There is insufficient evidence to support or refute the conclusion that dronabinol is
  an effective treatment for the symptoms of irritable bowel syndrome.

Some studies suggest that marijuana in the form of cannabidiol may be beneficial
in the treatment of inflammatory bowel diseases, including Crohn’s disease.

___ Parkinson’s disease
• There is insufficient evidence that cannabinoids are an effective treatment for the
  motor system symptoms associated with Parkinson’s disease or the levodopa-
  induced dyskinesia.

Evidence suggests that the endocannabinoid system plays a meaningful role in
certain neurodegenerative processes; thus, it may be useful to determine the

efficacy of cannabinoids in treating the symptoms of neurodegenerative
diseases. Small trials of oral cannabidiol preparations have demonstrated no
benefit compared to a placebo in ameliorating the side effects of Parkinson’s
disease. A seven-patient trial of nabixim suggested that it improved the
dyskinesia associated with levodopa therapy, but the sample size limits the
interpretation of the data. An observational study demonstrated improved

outcomes, but the lack of a control group and the small sample size are

limitations.

___ Multiple sclerosis
• There is substantial evidence that oral cannabinoids are an effective treatment for
  improving patient-reported multiple sclerosis spasticity symptoms, but limited
evidence for an effect on clinician-measured spasticity.

Based on evidence from randomized controlled trials included in systematic
reviews, an oral cannabidiol extract, nabixim, and orally administered THC are
probably effective for reducing patient-reported spasticity scores in patients with
MS. The effect appears to be modest. These agents have not consistently
demonstrated a benefit on clinician-measured spasticity indices.

___ Medical conditions of same kind or class as or comparable to the above qualifying
  medical conditions
• The qualifying physician has provided the patient or the patient’s caregiver a
  summary of the current research on the efficacy of marijuana to treat the patient’s
  medical condition.

• The summary is attached to this informed consent as Addendum ____.

Terminal conditions diagnosed by a physician other than the qualified physician
issuing the physician certification
• The qualifying physician has provided the patient or the patient’s caregiver a
  summary of the current research on the efficacy of marijuana to treat the patient’s
  terminal condition.

• The summary is attached to this informed consent as Addendum ____.

___ Chronic nonmalignant pain
• There is substantial evidence that cannabis is an effective treatment for chronic pain
  in adults.

The majority of studies on pain evaluated nabiximol outside the United States.
Only a handful of studies have evaluated the use of cannabis in the United
States, and all of them evaluated cannabis in flower form provided by the
National Institute on Drug Abuse. In contrast, many of the cannabis products
that are sold in state-regulated markets bear little resemblance to the products
that are available for research at the federal level in the United States. Pain
patients also use topical forms.

While the use of cannabis for the treatment of pain is supported by well-
controlled clinical trials, very little is known about the efficacy, dose, routes of
administration, or side effects of commonly used and commercially available

cannabis products in the United States.

i. That the patient’s de-identified health information contained in the physician
  certification and medical marijuana use registry may be used for research
  purposes.

___ The Department Health submits a data set to The Medical Marijuana Research
and Education Coalition for each patient registered in the medical marijuana use registry
that includes the patient’s qualifying medical condition and the daily dose amount and forms
of marijuana certified for the patient.

I have had the opportunity to discuss these matters with the physician and to ask
questions regarding anything I may not understand or that I believe needed to be clarified.
I acknowledge that Dr. ____ has informed me of the nature of a recommended treatment,
including but not limited to, any recommendation regarding medical marijuana.

Dr. ____ has also informed me of the risks, complications, and expected benefits of
any recommended treatment, including its likelihood of success and failure. I acknowledge
that Dr. ____ informed me of any alternatives to the recommended treatment,
including the alternative of no treatment, and the risks and benefits.
Medical Marijuana Consent Form

Dr. ___________ has explained the information in this consent form about the medical use of marijuana.

Patient (print name) ____________________________

Patient signature or signature of the parent or legal guardian if the patient is a minor:

_____________________________ Date _______________________

I have explained the information in this consent form about the medical use of marijuana to ____________________________ (print patient name).

Qualified physician signature: ____________________________ Date ____________

Witness: ____________________________ Date ____________
Regulations for Certifying Physicians

Issuing a Physician Certification for a Condition of the “Same Kind or Class”

If a physician issues a certification for a condition of the same kind or class as a listed condition, the physician must provide his or her applicable board (BOM or BOOM) with additional information within 14 days after issuing the physician certification. The additional information includes:

- Documentation supporting the qualified physician’s opinion that the medical condition is of the same kind or class as the conditions enumerated;
- Documentation that establishes the efficacy of marijuana as treatment for the condition;
- Documentation supporting the qualified physician’s opinion that the benefits of medical use of marijuana would likely outweigh the potential health risks for the patient;
- Any other documentation as required by board rule.

The DOH must also submit this additional documentation to the Coalition for Medical Marijuana Research and Education (Coalition) for research purposes.
Supply Limits

A qualified physician may not issue more than three 70-day supplies of marijuana. The DOH must quantify by rule a daily dose amount for each allowable form of marijuana. A physician may request an exception to the daily dose limit by electronically submitting a form adopted by the DOH in rule to the department. At a minimum, the form must include:

- The qualified patient’s qualifying medical condition;
- The dosage and route of administration that was insufficient to provide relief to the qualified patient;
- A description of how the patient will benefit from an increased amount;
- The minimum daily dose amount of marijuana that would be sufficient for the treatment of the qualified patient’s qualifying medical condition.

A qualified physician must provide the qualified patient’s records upon the request of the department. The department must approve or disapprove the request within 14 days after receipt of the complete documentation required by this paragraph or the request is deemed approved.
Patient Recertification

A physician must recertify a patient at least once every 30 weeks. In order to recertify a patient a physician must:

- Determine if the patient still meets the requirements to be issued a physician certification;

- Identify and document in the qualified patient’s medical records whether the qualified patient experienced either of the following related to the medical use of marijuana:
  - An adverse drug interaction with any prescription or nonprescription medication; or
  - A reduction in the use of, or dependence on, other types of controlled substances as defined in s. 893.02, F.S.
Residency Requirements

Before registering a patient with the registry, the DOH must determine whether the patient is a resident of Florida, which may include a “seasonal resident.” A “seasonal resident” includes any person who:

- Temporarily resides in this state for a period of at least 31 consecutive days in each calendar year;
- Maintains a temporary residence in this state;
- Returns to the state or jurisdiction of his or her residence at least one time during each calendar year; and
- Is registered to vote or pays income tax in another state or jurisdiction.

To prove residency a Florida resident must provide the DOH with copy of his or her valid Florida driver license or identification card. A minor must have a parent or legal guardian who meets this requirements and must also provide the DOH with a certified copy of his or her birth certificate or his or her school registration from a Florida K-12 school.
Other Regulations of Interest

Residency Requirements

A seasonal resident who cannot provide a copy of a Florida driver license or identification card may provide the DOH with two of the following to demonstrate a residential address in this state:

- A deed, mortgage, monthly mortgage statement, mortgage payment booklet or residential rental or lease agreement.;
- One proof of residential address from the seasonal resident’s parent, step-parent, legal; guardian or other person with whom the seasonal resident resides and a statement from the person with whom the seasonal resident resides stating that the seasonal resident does reside with him or her;
- A utility hookup or work order dated within 60 days before registration in the medical use registry;
- A utility bill, not more than 2 months old;
- Mail from a financial institution, including checking, savings, or investment account statements, not more than 2 months old;
- Mail from a federal, state, county, or municipal government agency, not more than 2 months old;
- Any other documentation that provides proof of residential address as determined by department rule.
Physician Monitoring

- The DOH is required to monitor physician registration in the registry and the issuance of physician certifications for practices that could facilitate the unlawful diversion or misuse of marijuana and take disciplinary actions as appropriate.

- Additionally, the BOM and the BOOM must jointly create a physician certification review panel to review all physician certifications submitted to the registry. The review panel is required to collect specified certification data and report such data individually by physician and in the aggregate by county and statewide. Starting January 1, 2018, and annually thereafter, the panel must submit a report to the Governor and the Legislature with findings and recommendations.
The Medical Marijuana Use Registry

- The previously named Compassionate Use Registry is **renamed the Medical Marijuana Use Registry**.

- The DOH is required to maintain the registry for physicians, patients, and caregivers.

- The electronic registry must be accessible online to law enforcement agencies, qualified physicians, and medical marijuana treatment centers (MMTC) to verify patient certifications.

- The registry must also be accessible to practitioners licensed to prescribe prescription drugs to ensure proper care for patients before prescribing medications that may interact with the medical use of marijuana.
Other Regulations of Interest

Patient and Caregiver Disqualification

The DOH may suspend or revoke the registration of any qualified patient or caregiver if he or she:

- Provides misleading, incorrect, false, or fraudulent information to the department;
- Obtains a supply of marijuana in an amount greater than the amount authorized by the physician certification;
- Falsifies, alters, or otherwise modifies an identification card;
- Fails to timely notify the department of any changes to his or her qualified patient status;
- Violates the requirements of this section or any rule adopted under this section.

The DOH must suspend the registration of a qualified patient who is charged with a violation of ch. 893, F.S., until the final disposition of the offense. The DOH may revoke the registration of a qualified patient or caregiver who cultivates, acquires, possesses, or delivers marijuana that was not obtained from an MMTC. Additionally, the DOH must revoke the registration of any qualified patient and his or her caregiver if such patient no longer meets the criteria of a qualified patient.
Caregivers

In order to qualify as a caregiver an individual must:

- Not be a qualified physician and not be employed by or have an economic interest in an MMTC or a marijuana testing laboratory;
- Be 21 years of age or older and a resident of this state;
- Agree in writing to assist with the qualified patient’s medical use of marijuana;
- Be registered in the medical marijuana use registry as a caregiver for no more than one qualified patient, with certain exceptions discussed below;
- Successfully complete a caregiver certification course developed and administered by the department or its designee, which must be renewed biennially. The price of the course may not exceed $100;
- Pass a background screening, unless the patient is a close relative of the caregiver.
Caregivers

A qualified patient may only have one caregiver unless:

- The qualified patient is a minor and the designated caregivers are parents or legal guardians of the qualified patient;
- The qualified patient is an adult who has an intellectual or developmental disability that prevents the patient from being able to protect or care for himself or herself without assistance or supervision and the designated caregivers are the parents or legal guardians of the qualified patient; or
- The qualified patient is admitted to a hospice program.
Caregivers

A caregiver may only assist one qualified patient unless:

- The caregiver is a parent or legal guardian of more than one minor who is a qualified patient;

- The caregiver is a parent or legal guardian of more than one adult who is a qualified patient and who has an intellectual or developmental disability that prevents the patient from being able to protect or care for himself or herself without assistance or supervision; or

- All qualified patients the caregiver has agreed to assist are admitted to a hospice program and have requested the assistance of that caregiver with the medical use of marijuana; the caregiver is an employee of the hospice; and the caregiver provides personal care or other services directly to clients of the hospice in the scope of that employment.
Caregivers

- A caregiver may not receive compensation for providing caregiver services other than actual expenses.

- A caregiver must be in immediate possession of his or her medical marijuana use registry identification card at all times when in possession of marijuana or a marijuana delivery device and must present his or her card if requested by a law enforcement officer.

- If a qualified patient is younger than 18 years of age, only a caregiver may purchase or administer marijuana for the patient’s medical use.
Federal Guidelines and Medical Marijuana
Federal Guidelines and Medical Marijuana

- According to Federal Law, marijuana is classified as a Schedule 1 Drug.

- A Schedule 1 Drug is defined as:
  - Drugs with no currently accepted medical use and a high potential for abuse.

- Medical Marijuana is not FDA approved for the treatment of any medical condition.

- Both medical and recreational marijuana use still remains illegal under federal law.
Currently, 29 other states have legislation in place allowing the use of marijuana for medicinal purposes (either full THC or low-THC/CBD).

8 states: Alaska, California, Colorado, Maine, Massachusetts, Nevada, Washington, Oregon, and Washington D.C. have legalized marijuana for both medicinal and recreational purposes.
• Previous U.S. Attorney Generals, have suggested focusing prosecutions on significant traffickers, not individual users.

• Therefore, in the past, U.S. attorneys have been asked not to prosecute patients “with cancer or other serious illnesses” who are using cannabis as part of a “recommended treatment regimen consistent with state law” or physicians who provide cannabis to such patients (Barber 2014).
Federal Guidelines and Medical Marijuana

- Since Federal Guidelines label marijuana as a Schedule I Drug, many research-based organizations, who receive federal funding, have voiced concerns regarding the study of medical cannabis;

- This concern was expressed by the University of Florida when SB 1030 originally passed in 2014. However, in 2015, the University changed its position on the basis of the FDA’s move to allow investigational new drug studies on “purified cannabidiols” for use as anti-seizure medications.
Federal Guidelines and Medical Marijuana

Banking

- The absence of banks providing financial services has resulted in marijuana becoming a prominently cash-only business. In order to address public safety concerns surrounding stockpiles of cash - the federal government issued guidelines intended to make financial services available to marijuana businesses providing legal services under a particular state’s marijuana laws. **Please see the following link for the Treasury Department’s The Financial Crimes Enforcement Network (“FinCEN”) guidelines:**


- Under the Treasury Department's plan “guidelines,” banks would file a suspicious activity report (SAR) for any financial transactions by any marijuana-related business. In turn, the financial institution is required to certify that it did not believe the business engaged in any illegal activity beyond dealing within the structure of the State’s marijuana laws;

- **According to Forbes Magazine:** The **guidelines have not persuaded many banks** to offer services because federal laws still prohibit such acts. **For a copy of the article please see the following link:**

Federal Guidelines and Medical Marijuana

Banking

- In Florida, there is one bank that is working with six currently licensed medical marijuana dispensing companies in Florida;
- First Green Bank, a community bank based in Orlando, has six branches, mostly in Central Florida and one in South Florida;
- With $662 million in assets, First Green Bank actively promotes environmental and social responsibility and is known for offering discounts and low-interest loans on "green" initiatives, like electric cars, LEED-certified construction and solar systems;
- Ken LaRoe, the bank’s founder has added cannabis to the list, because his wife used to use marijuana as treatment for seizures;
- Since medical marijuana is mostly a cash business, First Green bank hires armored cars to pick up the cash from the dispensaries. From there, the cash is sent to the Federal Reserve and then the money is electronically transferred to the bank.;
- Under guidance from the Federal Deposit Insurance Corporation and Florida Office of Financial Regulation, First Green must file regular reports of all marijuana transactions as “suspicious activities” under the “FinCen” guidelines (see previous slide).

Proposed Change to Federal Guidelines

- In early April 2016, the DEA released a lengthy memo to lawmakers saying it hopes to decide whether to change the schedule designation of marijuana in the first half of 2016.

- In August 2016 the DEA and FDA decided not to revise marijuana’s Schedule I status (no accepted medical use and high potential for abuse).

- "The DEA and the FDA continue to believe that scientifically valid and well-controlled clinical trials conducted under investigational new drug (IND) applications are the most appropriate way to conduct research on the medicinal uses of marijuana," said a statement from the DEA” (CNN August 12, 2016). [http://www.cnn.com/2016/08/11/health/dea-marijuana-schedule-i/](http://www.cnn.com/2016/08/11/health/dea-marijuana-schedule-i/)
Federal Guidelines and Medical Marijuana

The FDA & Medical Marijuana – Working Toward Valid Research

- The FDA has not approved any product containing or derived from botanical marijuana for any indication;
- The FDA has not found any such product to be safe or effective for the treatment of any disease or condition;
- Study of marijuana in clinical trial settings is needed to assess the safety and effectiveness of marijuana for medical use;
- According to the FDA, they will continue to facilitate the work of companies interested in appropriately bringing safe, effective, and quality products to market, including scientifically-based research concerning the medicinal uses of marijuana;
- The FDA believes that scientifically valid research conducted under an investigational new drug (IND) application is the best way to determine what patients could benefit from the use of drugs derived from marijuana.
Federal Guidelines and Medical Marijuana

The FDA & Medical Marijuana – Working Toward Valid Research

• Presently, clinical research using marijuana involves interactions with several federal agencies:

  o As a Schedule I controlled substance under the Controlled Substances Act, DEA provides researchers with a special registration and has certain requirements at the site marijuana will be studied;

  o The National Institute on Drug Abuse (NIDA) provides research-grade marijuana for scientific study. The agency is responsible for overseeing the cultivation of marijuana for medical research and has contracted with the University of Mississippi to grow marijuana for research at a secure facility. Marijuana of varying strengths and potencies is available;

  o Researchers work with the FDA and submit an IND application.
Legal Disclaimer

- This document does not constitute legal advice and is provided for informational purposes and your convenience only.

- The information contained in this document is provided to you “AS IS,” does not constitute legal advice, and is governed by our Terms and Conditions of Use. We make no claims, promises, or guarantees about the accuracy, completeness, or adequacy of the information contained in this document.

- The FOMA, their employees, agents, or others that provide information on or through this document will not be liable or responsible to you for any claim, loss, injury, liability, or damages related to your use of this document. Always seek the advice of a competent administrative/health care attorney for individual advice.